{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:34:02Z","timestamp":1793378042881,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.rmed.2026.108965","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:27:30Z","timestamp":1781911650000},"page":"108965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Should triple inhaled therapy be initiated earlier in the disease course of COPD to modify long-term outcomes, including mortality, exacerbations, and cardiovascular risk?"],"prefix":"10.1016","volume":"261","author":[{"given":"Vitaliano Nicola","family":"Quaranta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1563-6864","authenticated-orcid":false,"given":"Silvano","family":"Dragonieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3208-6977","authenticated-orcid":false,"given":"Giulia","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Camilo","family":"Signorello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Di Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Ciasullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejan","family":"Radovanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna Elisiana","family":"Carpagnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3462-8253","authenticated-orcid":false,"given":"Pierachille","family":"Santus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.rmed.2026.108965_bib2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S2213-2600(21)00511-7","article-title":"Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis","volume":"10","author":"Adeloye","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2026.108965_bib3","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1183\/09031936.00015608","article-title":"Pulmonary hypertension in COPD","volume":"32","author":"Chaouat","year":"2008","journal-title":"Eur. Respir. J."},{"issue":"8","key":"10.1016\/j.rmed.2026.108965_bib4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S2213-2600(15)00241-6","article-title":"Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"3","author":"Chen","year":"2015","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.rmed.2026.108965_bib5","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1378\/chest.12-2847","article-title":"Cardiovascular comorbidity in COPD: systematic literature review","volume":"144","author":"M\u00fcllerova","year":"2013","journal-title":"Chest"},{"issue":"18","key":"10.1016\/j.rmed.2026.108965_bib6","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024350","article-title":"Time-dependent risk of cardiovascular events following an exacerbation in patients with chronic obstructive pulmonary disease: post hoc analysis from the IMPACT trial","volume":"11","author":"Dransfield","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"6","key":"10.1016\/j.rmed.2026.108965_bib7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1042\/CS20210835","article-title":"Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics","volume":"136","author":"Brassington","year":"2022","journal-title":"Clin Sci (Lond)."},{"issue":"1","key":"10.1016\/j.rmed.2026.108965_bib8","first-page":"33","article-title":"Mortality risk and serious cardiopulmonary events in moderate-to-severe COPD: post hoc analysis of the IMPACT trial","volume":"10","author":"Wells","year":"2023","journal-title":"Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.rmed.2026.108965_bib9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejim.2025.01.016","article-title":"Risk trajectory of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"135","author":"Pirera","year":"2025","journal-title":"Eur. J. Intern. Med."},{"issue":"1","key":"10.1016\/j.rmed.2026.108965_bib10","article-title":"Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study","volume":"11","author":"Rothnie","year":"2024","journal-title":"BMJ Open Respir. Res."},{"key":"10.1016\/j.rmed.2026.108965_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107694","article-title":"The long-term clinical and economic benefits of treating advanced COPD patients with single-inhaler triple therapy in Quebec, Canada - the IMPACT trial","volume":"231","author":"Risebrough","year":"2024","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2026.108965_bib12","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00881-2020","article-title":"The right treatment for the right patient with COPD: lessons from the IMPACT trial","volume":"55","author":"Stolz","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.rmed.2026.108965_bib13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","article-title":"Reduced all-cause mortality in the ETHOS trial of Budesonide\/Glycopyrrolate\/Formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study","volume":"203","author":"Martinez","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2026.108965_bib14","article-title":"Reduction in fatal events with extrafine inhaled corticosteroid (ICS)-Containing medications: results of stratified safety pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies","volume":"52","author":"Fabbri","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.rmed.2026.108965_bib15","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00235-2019","article-title":"Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation","volume":"53","author":"Singh","year":"2019","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2026.108965_bib16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2147\/COPD.S196383","article-title":"Extrafine triple therapy delays COPD clinically important deterioration vs ICS\/LABA, LAMA, or LABA\/LAMA","volume":"14","author":"Singh","year":"2019","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2026.108965_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12931-025-03234-5","article-title":"Step up to triple therapy versus switch to dual bronchodilator therapy in patients with COPD on an inhaled corticosteroid\/long-acting \u03b22-agonist: post-hoc analyses of KRONOS","volume":"26","author":"Singh","year":"2025","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2026.108965_bib18","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.2147\/COPD.S370577","article-title":"Cost-effectiveness of Single- versus multiple-inhaler triple therapy in a UK COPD population: the INTREPID trial","volume":"17","author":"Halpin","year":"2022","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"2","key":"10.1016\/j.rmed.2026.108965_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1164\/rccm.202312-2311OC","article-title":"Effect of triple therapy on cardiovascular and severe cardiopulmonary events in chronic obstructive pulmonary disease: a post hoc analysis of a randomized, double-blind, phase 3 clinical trial (ETHOS)","volume":"211","author":"Singh","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2026.108965_bib20","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1183\/23120541.00827-2024","article-title":"Should all patients with COPD be treated with inhaled triple therapy?","volume":"11","author":"Sin","year":"2025","journal-title":"ERJ Open Res"},{"issue":"2","key":"10.1016\/j.rmed.2026.108965_bib21","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00171-2024","article-title":"ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPD","volume":"65","author":"Wade","year":"2025","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2026.108965_bib22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2147\/COPD.S446636","article-title":"Exacerbation burden in COPD and occurrence of mortality in a cohort of Italian patients: results of the gulp study","volume":"19","author":"Santus","year":"2024","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2026.108965_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2025.102360","article-title":"Mitigating systemic corticosteroid risks in COPD: a call for earlier triple therapy initiation","volume":"90","author":"Nannini","year":"2025","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.rmed.2026.108965_bib24","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1007\/s12325-023-02583-1","article-title":"DElaying disease progression in COPD with early initiation of dual bronchodilator or triple inhaled PharmacoTherapy (DEPICT): a predictive modelling approach","volume":"40","author":"Singh","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.rmed.2026.108965_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2025.1680080","article-title":"Effect of triple inhaled therapy on MACE and cardiovascular events in COPD: a systematic review and meta-analysis","volume":"12","author":"Calder\u00f3n-Montero","year":"2025","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.rmed.2026.108965_bib26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1164\/rccm.201711-2239OC","article-title":"Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial","volume":"198","author":"Kunisaki","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"18","key":"10.1016\/j.rmed.2026.108965_bib27","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2026.108965_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.rmed.2026.108965_bib29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1164\/rccm.202012-4300ED","article-title":"Reigniting the TORCH: chronic obstructive pulmonary disease mortality and inhaled corticosteroids revisited","volume":"203","author":"Calverley","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10","key":"10.1016\/j.rmed.2026.108965_bib30","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.arbres.2025.02.004","article-title":"All-cause and cardiovascular mortality with single inhaler triple therapy versus double therapies for COPD: a systematic review and metanalysis","volume":"61","author":"Hammadi","year":"2025","journal-title":"Arch. Bronconeumol."},{"issue":"10","key":"10.1016\/j.rmed.2026.108965_bib31","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S2213-2600(19)30397-2","article-title":"The acute COPD exacerbation prediction tool (ACCEPT): a modelling study","volume":"8","author":"Adibi","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2026.108965_bib32","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.2147\/COPD.S475748","article-title":"Economic analysis of new single-inhaler triple therapies in patients with COPD in the UK","volume":"20","author":"Cai","year":"2025","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"10","key":"10.1016\/j.rmed.2026.108965_bib33","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/thorax-2022-219382","article-title":"Estimating individual treatment effects on COPD exacerbations by causal machine learning on randomised controlled trials","volume":"78","author":"Verstraete","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2026.108965_bib34","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2147\/COPD.S336297","article-title":"Evaluating triple therapy treatment pathways in Chronic Obstructive Pulmonary Disease (COPD): a machine-learning predictive model","volume":"17","author":"Bogart","year":"2022","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"4","key":"10.1016\/j.rmed.2026.108965_bib35","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/0272989X16653118","article-title":"Development of the galaxy Chronic Obstructive Pulmonary Disease (COPD) model using data from ECLIPSE: internal validation of a linked-equations cohort model","volume":"37","author":"Briggs","year":"2017","journal-title":"Med. Decis. Mak."},{"key":"10.1016\/j.rmed.2026.108965_bib36","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2147\/COPD.S240556","article-title":"Cost-effectiveness analysis of a once-daily single-inhaler triple therapy for patients with Chronic Obstructive Pulmonary Disease (COPD) using the FULFIL trial: a Spanish perspective","volume":"15","author":"Schroeder","year":"2020","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2026.108965_bib37","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.csbj.2025.01.015","article-title":"Development and validation of a novel AI-derived index for predicting COPD medical costs in clinical practice","volume":"27","author":"Liu","year":"2025","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"7","key":"10.1016\/j.rmed.2026.108965_bib38","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/thx.2010.152876","article-title":"Lung function impairment, COPD hospitalisations and subsequent mortality","volume":"66","author":"Garcia-Aymerich","year":"2011","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.rmed.2026.108965_bib39","first-page":"317","article-title":"Inhaled corticosteroids and risk of cardiovascular disease in chronic obstructive pulmonary disease: a systematic review and meta-regression","volume":"10","author":"Gadhvi","year":"2023","journal-title":"Chronic Obstr Pulm Dis"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126003331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126003331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:41:07Z","timestamp":1793374867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611126003331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":38,"alternative-id":["S0954611126003331"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108965","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should triple inhaled therapy be initiated earlier in the disease course of COPD to modify long-term outcomes, including mortality, exacerbations, and cardiovascular risk?","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108965","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108965"}}